Clinical trials: Gastrointestinal
Colorectal Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer.
- Trial name
- NCT01399190
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- 9 sites in Slovakia
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer, Precancerous Condition
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of esomeprazole and aspirin may prevent esophageal cancer in patients with Barrett's metaplasia.
- Trial name
- AspECT (NCT00357682)
- Testing
- Esomeprazole, Aspirin
- Volunteers
- 2,557 people
- Sponsor
- University of Oxford
Hepatitis C, Renal Insufficiency, Chronic
HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant
The purpose of this study is to determine whether patients treated for chronic hepatitis C (HCV) with zepatier (grazoprevir/elbasvir) prior to kidney transplant will have a stronger immune response compared to patients treated…
- Conditions
- Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney
- Trial name
- NCT02902120
- Testing
- Post-transplant Grazoprevir and Elbasvir
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
Digestive System Disease
Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy
The purpose of the protocol is to demonstrate that Eziclen®/Izinova®, an osmotic sulphate-based laxative preparation given on the day before colonoscopy has non-inferior efficacy to Klean-Prep® (polyethylene glycol…
- Trial name
- EASYKID (NCT03008460)
- Testing
- Eziclen®/Izinova®, Klean-Prep®
- Where
- 24 sites in Czechia, France and 4 more
- Volunteers
- 250 people
- Sponsor
- Ipsen
Stomach Ulcer, Duodenal Ulcer
A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
The purpose of this study is to determine whether lansoprazole, once daily (QD), compared to gefarnate, twice daily (BID), is effective in preventing the recurrence of gastric and duodenal ulcers in patients receiving long term…
- Trial name
- NCT00762359
- Testing
- Lansoprazole, Gefarnate
- Where
- 65 sites in Japan
- Volunteers
- 461 people
- Sponsor
- Takeda
Colorectal Neoplasms
A 4-arm Clinical Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy
Adenoma detection rate (ADR) is a validated marker for reducing the risk of interval colorectal cancer after a screening colonoscopy.
- Trial name
- NCT02345889
- Testing
- Colonoscopy with EndoCuff™, FUSE® Colonoscopy, Colonoscopy with EndoRings™
- Where
- United States
- Volunteers
- 1,262 people, healthy volunteers welcome
- Sponsor
- Indiana University
Cancer
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
This was a four part, phase I/II study aimed to evaluate the safety, tolerability and efficacy of combination of an anti-EGFR antibody panitumumab (P) either with a BRAF inhibitor (dabrafenib (D); GSK2118436) alone or with the…
- Trial name
- NCT01750918
- Testing
- Dabrafenib, Trametinib, Panitumumab
- Where
- 20 sites in United States, Belgium and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC.
- Trial name
- NCT03519997
- Testing
- Pembrolizumab, Bavituximab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- David Hsieh
Warts, Genital, Neoplasms, Anal
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)
The purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate the efficacy of V503 in preventing human papillomavirus (HPV)-related anogenital persistent infection, and to evaluate the…
- Trial name
- NCT04635423
- Testing
- V503
- Where
- 22 sites in Japan
- Volunteers
- 1,059 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Idiopathic Gastroparesis
A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis
Gastroparesis is a disorder characterized by impaired gastric emptying in the absence of obstruction in the proximal GI tract. It is a common condition affecting up to 5 million persons in the United States alone.
- Trial name
- NCT01625923
- Testing
- Olanzapine
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan
Anal Cancer
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093379
- Testing
- Capecitabine, Oxaliplatin, Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Tetanus, Diphtheria
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose
The current trial will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A vaccine when administered as a booster dose following priming in the first year of life with the same vaccine.
- Conditions
- Tetanus, Diphtheria, Haemophilus Influenzae Type b, Hepatitis B
- Trial name
- NCT01171989
- Testing
- GSK2202083A vaccine, Infanrix hexa™, Menjugate™
- Where
- 9 sites in Poland
- Volunteers
- 391 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis, Crohn Disease
A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, people with ulcerative colitis or Crohn's disease will be treated with vedolizumab.
- Trial name
- NCT04804540
- Testing
- Vedolizumab IV
- Where
- 17 sites in India
- Volunteers
- 150 people
- Sponsor
- Takeda
Primary Biliary Cholangitis
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).
- Trial name
- NCT05239468
- Testing
- Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg
- Where
- 26 sites in United States, Argentina and 2 more
- Volunteers
- 72 people
- Sponsor
- Intercept Pharmaceuticals
Chronic Gastrointestinal Graft vs Host Disease
Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
- Trial name
- NCT01925950
- Testing
- orBec
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Soligenix
Pancreatic Cysts
A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration
Our hypothesis is that a single dose of antibiotics at time of EUS-guided pancreatic cyst aspiration is equally effective to the usual regimen of 3 days of post-procedural antibiotics.
- Trial name
- NCT01929460
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Kaiser Permanente
Eosinophilic Esophagitis
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538.
- Trial name
- NCT04991935
- Testing
- CC-93538
- Where
- 167 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Celgene
Carcinoma, Hepatocellular
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients
- Trial name
- NCT00987935
- Testing
- Sorafenib, BIBF 1120
- Where
- 16 sites in South Korea, Taiwan
- Volunteers
- 134 people
- Sponsor
- Boehringer Ingelheim
Esophageal Carcinoma
Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer
This randomized phase II trial studies how well botulinum toxin type A works in preventing complication after surgery in patients with esophageal cancer.
- Trial name
- NCT02965976
- Testing
- Botulinum Toxin Type A, Esophagectomy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.